Furthermore, since the discovery of NPM1 mutations in AML, several studies have molecularly investigated the presence of NPM1 mutations in non-acute MNs with <20% blasts, namely, MDS and MDS/MPN cases, either by single-gene PCR assays or by newer high-throughput molecular techniques, such as NGS, as summarized in Table 1 [37,40,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86]. This evidence concerns the gene NPM1 and myeloproliferative disorder.